{"id":745335,"date":"2016-08-08T16:05:00","date_gmt":"2016-08-08T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/"},"modified":"2025-11-07T01:25:41","modified_gmt":"2025-11-07T06:25:41","slug":"results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/","title":{"rendered":"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the publication of results from <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688%3Fterm%3DC-EDGE%2BCO-STAR%26rank%3D1&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=C-EDGE+CO-STAR&amp;index=1&amp;md5=49690b8cb7cd08e80bccc724c392de44\" rel=\"nofollow\"><br \/>\n<i>C-EDGE<br \/>\n      CO-STAR<\/i><br \/>\n<\/a>. <i>C-EDGE CO-STAR<\/i> is a Phase 3 trial evaluating the<br \/>\n      use of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets in<br \/>\n      patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6<br \/>\n      infection receiving opioid agonist therapy (OAT) (methadone and<br \/>\n      buprenorphine), commonly used to treat opioid addiction. The results,<br \/>\n      recently published online in the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fannals.org%2Fjournal.aspx&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=Annals+of+Internal+Medicine&amp;index=2&amp;md5=601e3929638e045bad59feabf32f6434\" rel=\"nofollow\"><br \/>\n<i>Annals<br \/>\n      of Internal Medicine<\/i><br \/>\n<\/a>, showed treatment with 12 weeks of ZEPATIER<br \/>\n      resulted in high rates of sustained virologic response 12 weeks after<br \/>\n      the completion of therapy (SVR12, considered virologic cure based on<br \/>\n      undetectable HCV RNA levels). These results and full study design were<br \/>\n      previously presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fresearch-and-development-news%2Fmerck-announces-presentation-phase-3-results-investigatio&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE&amp;index=3&amp;md5=ff878dfe91d8f7da00d549f0a6c16888\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup><br \/>\n<\/a> in November 2015.\n    <\/p>\n<p>\n      \u201c<i>C-EDGE CO-STAR<\/i> is the first phase 3 clinical trial dedicated to<br \/>\n      evaluating direct-acting antiviral therapy for chronic hepatitis C<br \/>\n      infection in patients on opioid agonist therapy without excluding<br \/>\n      patients actively using drugs with high abuse potential,\u201d said Dr. Alain<br \/>\n      Litwin, professor of medicine and psychiatry and behavioral sciences at<br \/>\n      Albert Einstein College of Medicine, New York. \u201cThis study demonstrates<br \/>\n      that people who inject drugs can be effectively treated with<br \/>\n      direct-acting antiviral therapy.\u201d\n    <\/p>\n<p>\n      The published efficacy results from the randomized, double-blind,<br \/>\n      placebo-controlled <i>C-EDGE CO-STAR<\/i> trial showed 92 percent<br \/>\n      (184\/201) of patients receiving ZEPATIER for 12 weeks in the study\u2019s<br \/>\n      immediate treatment group achieved SVR12, with comparable rates across<br \/>\n      GT1a (94%, 144\/154), GT1b (93%, 28\/30) and GT4 (92%, 11\/12) patients; in<br \/>\n      the limited number of GT6 patients, SVR12 was 20 percent (1\/5). These<br \/>\n      results classify patients who cleared their baseline infection but<br \/>\n      subsequently acquired a new infection as treatment failures; previously<br \/>\n      presented results from this trial considered these patients as treatment<br \/>\n      successes, according to the study protocol. A supportive analysis showed<br \/>\n      that the vast majority of patients were adherent to therapy, despite<br \/>\n      ongoing use of drugs of potential abuse (e.g., cocaine, heroin,<br \/>\n      amphetamines) by the majority of patients throughout the trial. The<br \/>\n      rates of adverse events were generally comparable between active<br \/>\n      treatment and placebo groups, with the most common adverse events<br \/>\n      (greater than 10%) in both groups including fatigue (16%, 20%), headache<br \/>\n      (12%, 13%) and nausea (11%, 9%), respectively. Secondary efficacy<br \/>\n      endpoint (SVR24) and reinfection analyses were presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmerck-announces-results-phase-3-studies-zepatier-elbasvir-and-graz&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=The+International+Liver+Congress%E2%84%A2&amp;index=4&amp;md5=f41b1a2404c5082f99b247e8dbe9e27f\" rel=\"nofollow\">The<br \/>\n      International Liver Congress\u2122<\/a> in April 2016.\n    <\/p>\n<p>\n      \u201cMerck continues to take a leadership role in exploring the potential to<br \/>\n      treat chronic hepatitis C infection in underserved and undertreated<br \/>\n      patient populations, including those who continue to use illicit drugs,\u201d<br \/>\n      said Dr. Eliav Barr, vice president, infectious diseases, Merck Research<br \/>\n      Laboratories. \u201cThese findings contribute to the robust body of evidence<br \/>\n      supporting the efficacy and safety profile of ZEPATIER in a broad range<br \/>\n      of patients with chronic hepatitis C genotype 1 or genotype 4 infection.\u201d\n    <\/p>\n<p>\n      <b>About ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg Tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, a HCV<br \/>\n      NS5A inhibitor, and grazoprevir, an HCV NS3\/4A protease inhibitor, and<br \/>\n      is indicated with or without ribavirin (RBV) for treatment of chronic<br \/>\n      HCV GT 1 or 4 infection in adults. ZEPATIER is not indicated to treat<br \/>\n      chronic HCV GT6 infection.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER<\/b>\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3) inhibitors<br \/>\n      (e.g., atazanavir, darunavir, lopinavir, saquinavir, tipranavir,<br \/>\n      cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.g.,<br \/>\n      carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and efavirenz. If<br \/>\n      ZEPATIER is administered with RBV, healthcare professionals should refer<br \/>\n      to the prescribing information for RBV as the contraindications,<br \/>\n      warnings and precautions, adverse reactions and dosing for RBV also<br \/>\n      apply to this combination regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER if ALT levels remain persistently<br \/>\n      greater than 10 times ULN. ZEPATIER should be discontinued if ALT<br \/>\n      elevation is accompanied by signs or symptoms of liver inflammation or<br \/>\n      increasing conjugated bilirubin, alkaline phosphatase, or international<br \/>\n      normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to adverse<br \/>\n      reactions or reduced therapeutic effect due to drug interactions.<br \/>\n      Certain strong CYP3A inhibitors may increase the plasma concentration of<br \/>\n      ZEPATIER, leading to possibly clinically significant adverse reactions.<br \/>\n      Moderate CYP3A inducers may decrease the plasma concentration of<br \/>\n      ZEPATIER, leading to reduced therapeutic effect and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER with these drugs is not<br \/>\n      recommended. Physicians should consult the Prescribing Information for<br \/>\n      potential drug interactions.\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>Selected Dosage and Administration Information for ZEPATIER (elbasvir<br \/>\n      and grazoprevir)<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a single tablet taken once daily. The recommended dosing is<br \/>\n      12 or 16 weeks with or without RBV, depending on HCV genotype, prior<br \/>\n      treatment history and, for patients with genotype 1a infection, presence<br \/>\n      of certain baseline NS5A resistance-associated polymorphisms. See<br \/>\n      Prescribing Information for ZEPATIER for specific dosage regimens and<br \/>\n      durations. Refer to RBV prescribing information for RBV dosing and<br \/>\n      dosage modifications when ZEPATIER is given with RBV. To determine<br \/>\n      dosage regimen and duration of ZEPATIER for genotype 1a patients,<br \/>\n      testing for the presence of virus with one or more baseline NS5A<br \/>\n      resistance-associated polymorphisms at positions 28, 30, 31, or 93 is<br \/>\n      recommended prior to initiating treatment.\n    <\/p>\n<p>\n      <b>About Chronic HCV Infection and Injection Drug Use<\/b>\n    <\/p>\n<p>\n      Injection drug use is responsible for the majority of new and existing<br \/>\n      HCV infections in high-income countries. It is estimated that 60 to 80<br \/>\n      percent of people who inject drugs are tested positive with chronic HCV<br \/>\n      infection.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been at the forefront of the response<br \/>\n      to the HCV epidemic. Merck\u2019s chronic HCV clinical development programs<br \/>\n      have included more than 135 clinical trials in approximately 40<br \/>\n      countries and have enrolled nearly 10,000 participants. As part of our<br \/>\n      longstanding leadership in infectious diseases, Merck collaborates with<br \/>\n      the scientific and patient communities to develop and deliver innovative<br \/>\n      solutions to support people living with chronic HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=a6497db2d77fe68e63e03537d4823b28\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=10cc2546b61224ea1b7bf2cf2d057640\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=fd1a1eaf198ccf49a611310d8ca899e6\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=ea4a6606d1fe81a53e342707d9739718\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=ef56da9cb4a10685f5023bd8528ec399\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=8f5147f57ac314ee56efdd67f33a02d6\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      # # #\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=11&amp;md5=7811ad78d4b28889fa9ce1fc336c133b\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51397104&amp;newsitemid=20160808006260&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=12&amp;md5=676540b59d8b4d11bb2e41968ac6b65c\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160808006260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investor:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. The results, recently published online in the Annals of Internal Medicine , showed treatment with 12 weeks of ZEPATIER resulted in high rates of sustained virologic response 12 weeks after the completion of therapy (SVR12, considered virologic cure based on undetectable HCV RNA levels). These results and full study design were previously presented at The Liver Meeting\u00ae in November 2015. \u201cC-EDGE CO-STAR is the first phase 3 clinical trial dedicated to evaluating direct-acting antiviral therapy for chronic hepatitis C infection in patients on opioid<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,55,289,56],"class_list":["post-745335","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. The results, recently published online in the Annals of Internal Medicine , showed treatment with 12 weeks of ZEPATIER resulted in high rates of sustained virologic response 12 weeks after the completion of therapy (SVR12, considered virologic cure based on undetectable HCV RNA levels). These results and full study design were previously presented at The Liver Meeting\u00ae in November 2015. \u201cC-EDGE CO-STAR is the first phase 3 clinical trial dedicated to evaluating direct-acting antiviral therapy for chronic hepatitis C infection in patients on opioid\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\\\/\",\"name\":\"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-08-08T16:05:00+00:00\",\"dateModified\":\"2025-11-07T06:25:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/","og_locale":"en_US","og_type":"article","og_title":"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. The results, recently published online in the Annals of Internal Medicine , showed treatment with 12 weeks of ZEPATIER resulted in high rates of sustained virologic response 12 weeks after the completion of therapy (SVR12, considered virologic cure based on undetectable HCV RNA levels). These results and full study design were previously presented at The Liver Meeting\u00ae in November 2015. \u201cC-EDGE CO-STAR is the first phase 3 clinical trial dedicated to evaluating direct-acting antiviral therapy for chronic hepatitis C infection in patients on opioid","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:41+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/","name":"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-08-08T16:05:00+00:00","dateModified":"2025-11-07T06:25:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-evaluating-zepatier-elbasvir-and-grazoprevir-in-patients-with-chronic-hepatitis-c-receiving-treatment-for-opioid-dependence-published-in-annals-of\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results from Merck\u2019s Phase 3 Study Evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4f09da18-d27e-473c-9d96-a6e74b5fcb52","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745335\/revisions"}],"predecessor-version":[{"id":3674742,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745335\/revisions\/3674742"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745335"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}